| 8.94 -0.26 (-2.83%) | 09-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.18 | 1-year : | 14.1 |
| Resists | First : | 10.43 | Second : | 12.07 |
| Pivot price | 9.87  |
|||
| Supports | First : | 7.76 | Second : | 6.46 |
| MAs | MA(5) : | 9.31 |
MA(20) : | 10.07 |
| MA(100) : | 9.48 |
MA(250) : | 10.46 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 34.2 |
D(3) : | 36.9 |
| RSI | RSI(14): 41.4 |
|||
| 52-week | High : | 16.19 | Low : | 5.45 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ RGNX ] has closed above bottom band by 28.0%. Bollinger Bands are 2.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.23 - 9.29 | 9.29 - 9.34 |
| Low: | 8.72 - 8.77 | 8.77 - 8.83 |
| Close: | 8.83 - 8.93 | 8.93 - 9.04 |
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
Sat, 05 Sep 2026
Regenxbio Stock Price Forecast. Should You Buy RGNX? - StockInvest.us
Fri, 04 Sep 2026
REGENXBIO Inc. (RGNX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Wed, 02 Sep 2026
How Regenxbio Inc. (RGNX) Affects Rotational Strategy Timing - Stock Traders Daily
Tue, 25 Aug 2026
REGENXBIO (RGNX) grants $550K equity to new board hire - Stock Titan
Mon, 24 Aug 2026
RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold - GlobeNewswire
Sun, 23 Aug 2026
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights - Eastern Progress
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 66 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 6.5 (%) |
| Held by Institutions | 65.5 (%) |
| Shares Short | 8,200 (K) |
| Shares Short P.Month | 8,630 (K) |
| EPS | -3.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.33 |
| Profit Margin | -112.6 % |
| Operating Margin | 27 % |
| Return on Assets (ttm) | -21.3 % |
| Return on Equity (ttm) | -137.7 % |
| Qtrly Rev. Growth | 405.7 % |
| Gross Profit (p.s.) | -1.19 |
| Sales Per Share | 2.64 |
| EBITDA (p.s.) | -2.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -247 (M) |
| Levered Free Cash Flow | -184 (M) |
| PE Ratio | -2.37 |
| PEG Ratio | 0 |
| Price to Book value | 6.72 |
| Price to Sales | 3.38 |
| Price to Cash Flow | -2.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|